Is BioAge Labs, Inc. (NASDAQ:BIOA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating BioAge Labs, Inc. at current levels.
Failed obesity bet became a stealth NLRP3 platform play, and the market still prices it like a one-trick pony that already broke.
Where BIOA is headed
Eighteen months ago BioAge was left for dead. Azelaprag, the APJ agonist meant to ride the GLP-1 obesity wave alongside tirzepatide, blew up in the STRIDES Phase 2 readout in late 2024 on liver safety signals. The stock collapsed from $24 to under $4. Management did something most failed biotechs don't do, they stopped pretending the dead horse would run and pivoted hard into BGE-102, the oral brain-penetrant NLRP3 inhibitor sitting in the pipeline.
Read the full Compass Direction on BIOA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $15.80).
See the full BIOA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is BioAge Labs, Inc. (NASDAQ:BIOA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating BioAge Labs, Inc. at current levels. Failed obesity bet became a stealth NLRP3 platform play, and the market still prices it like a one-trick pony that already broke.
What is BIOA's Compass Score?
BioAge Labs, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for BIOA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the BIOA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.